Tag: countries

JOHANNESBURG, June 18, 2025 (GLOBE NEWSWIRE) -- Renergen is pleased to announce that preferred bidder status has been awarded to He4u consortium for the design, procurement, delivery, construction and commissioning for phase 2 of the Tetra4 LNG and helium liquefaction project, comprising of, Chart Industries Inc. (NYSE: GTLS), Wilson Bayly Holmes - Ovcon Ltd (JSE: WBO), and Aurex Constructors. The appointment of an acceptable EPC contractor in Phase 2 was one of the two remaining conditions for the DFC Phase 2 loan.

-  Prenetics adopts proven corporate Bitcoin strategy inspired by MicroStrategy's ~$40B Bitcoin holdings and Metaplanet's meteoric treasury transformation

Statkraft, Europe's largest producer of renewable energy, will further strengthen its core competitive advantages by prioritising its flexible hydropower fleet in the Nordics, industry-leading market operations – and solar, wind and battery activities in Europe and South America. 

The global patient handling equipment market is set to grow from USD 12.4 billion in 2025 to USD 16.4 billion by 2030, at a CAGR of 5.8%. Key growth drivers include the aging population and rising prevalence of cardiovascular diseases, necessitating advanced and ergonomic devices. A surge in home healthcare services across North America, Europe, and Asia Pacific further boosts demand. The patient transfer devices segment, particularly patient lifts, dominates due to increasing awareness and musculoskeletal injuries among healthcare staff. The Asia Pacific region, driven by countries like China and India, is predicted to grow significantly. Leading companies include Arjo, Stryker, and Baxter International.

CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 to <16. Both non-ambulatory and ambulatory participants may qualify for the study. Participants will be randomized 2:1 to receive omaveloxolone or placebo once a day for 52 weeks before having the opportunity to move into the open-label extension (OLE). Currently, omaveloxolone is commercialized under the brand name SKYCLARYS^® in over 40 countries, including in the U.S. and the European Union, and is the only approved product for FA in adults and adolescents aged 16 years and older.